437TiP An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC)
M. George(Rutgers, The State University of New Jersey), Jean‐Sébastien Frenel(Institut de Cancérologie de l'Ouest), J. Cortés, M. Schmidt(Johannes Gutenberg University Mainz), José Á. García-Sáenz(Hospital Clínico San Carlos), Sibel Blau(Northwest Medical Specialties), Nihal Abdulla(Cancer Clinic), Mitsuyo Nishimura(Japanese Foundation For Cancer Research), Hitomi Sakai(Showa University), Suma Babu(Fort Wayne Medical Institute), Nicholas P. McAndrew(University of California, Los Angeles), Azka Ali(Cleveland Clinic), Matea Pavic(Centre Hospitalier Universitaire de Sherbrooke), K. Jhaveri(Memorial Sloan Kettering Cancer Center), Joseph Jones(Avera Health), H.S. Rugo(University of California, San Francisco), Kalgi Mody(Eisai (United States)), Abigail Smith(Eisai (United Kingdom)), Tetsuo Yamashita(Kanagawa Prefectural Hospital Organization)
Cited by 0Open Access
Abstract
Related Papers
No related papers found
Powered by citation graph analysis